Cargando…
Do cytomegalovirus infections affect the daratumumab treatment course in multiple myeloma patients? – Literature review
INTRODUCTION: Multiple myeloma is a progressive and incurable hematological disease characterized by disordered and clonal multiplication of plasmacytes in the bone marrow. The main clinical manifestations are caused by the presence of neoplastic cells in bone tissue, as well as the excessive produc...
Autores principales: | Ferreira, Luana Mota, Cerezer, Jaderson Lima, Gehrcke, Mailine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Hematologia e Hemoterapia
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211630/ https://www.ncbi.nlm.nih.gov/pubmed/32737019 http://dx.doi.org/10.1016/j.htct.2020.05.009 |
Ejemplares similares
-
Daratumumab for the Treatment of Multiple Myeloma
por: Plesner, Torben, et al.
Publicado: (2018) -
Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment
por: Frerichs, Kristine A., et al.
Publicado: (2019) -
Daratumumab in dialysis-dependent multiple myeloma
por: Jeyaraman, Preethi, et al.
Publicado: (2020) -
Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
por: Frerichs, Kristine A., et al.
Publicado: (2021) -
Potential role of daratumumab in the treatment of multiple myeloma
por: Khagi, Yulian, et al.
Publicado: (2014)